Shares of Profound Medical Corp. (PROF) have gained nearly 14% over the past 1 month and trade around $5.
This commercial-stage medical device company focuses on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue. Its lead product is the FDA-cleared TULSA-PRO system, a minimally invasive, AI-powered, MRI-guided, and robotically driven solution for prostate disease, which is covered by Medicare. The device is FDA-cleared, CE Marked and also approved in Canada.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com